AstraZeneca plc (NASDAQ: AZN) – Global Pharmaceuticals

NASDAQ: AZN | LSE: AZN | Market Cap: ~$230 billion USD | Sector: Healthcare/Pharmaceuticals

Company Overview

AstraZeneca plc is a British‑Swedish multinational pharmaceutical company focused on innovative, patent‑protected prescription medicines. It has leading positions in oncology, cardiovascular, renal & metabolism (CVRM), respiratory & immunology, and rare diseases (via Alexion). AstraZeneca has transformed over the last decade from a patent‑cliff story into one of the fastest‑growing Big Pharma companies.

Key Facts

Formed: 1999 (merger of Astra AB of Sweden and Zeneca Group of the UK)
Headquarters: Cambridge, United Kingdom
Listings: London Stock Exchange (AZN, FTSE 100), NASDAQ (AZN – ADR)
CEO: Pascal Soriot (since 2012)
Employees: ~89,000 globally
Operations: 100+ countries
2023 Revenue: ~$45–47 billion USD (constant‑currency growth high single digits)

Strategic Profile

Pivoted from mature primary‑care drugs to oncology, specialty care, biologics, and rare diseases
Major acquisitions: Alexion (2021, $39B – rare diseases), multiple smaller oncology deals
Heavy R&D: ~20% of revenue reinvested in research

Business Segments

Revenue by Therapy Area (FY2023, approximate)

Therapy Area	Revenue (USD)	% of Total
Oncology	~$17B	~37%
CVRM (Cardiovascular, Renal & Metabolism)	~$11B	~24%
Rare Disease (Alexion)	~$7B	~15%
Respiratory & Immunology	~$7B	~15%
Other (including vaccines, infection, neuroscience)	~$3–4B	~9%

Total Revenue: ~$45–47B (2023, continuing business)

1. Oncology (Cancer) – Flagship Franchise

Oncology is AstraZeneca’s largest and fastest‑growing business, driven by targeted therapies, immuno‑oncology, and ADCs (antibody‑drug conjugates).

Key Oncology Products

TAGRISSO® (osimertinib)

Indications: EGFR‑mutated non‑small cell lung cancer (NSCLC) – 1L, 2L, and adjuvant
Mechanism: Third‑generation EGFR TKI that crosses blood–brain barrier
2023 Sales: ~$5–6B (AstraZeneca’s #1 product)
Strength: Standard of care in EGFRm NSCLC worldwide

IMFINZI® (durvalumab)

Indications: Stage III unresectable NSCLC (post‑chemoradiation), ES‑SCLC, biliary tract cancer, and others
Mechanism: PD‑L1 checkpoint inhibitor
2023 Sales: ~$3–4B
Role: Backbone in multiple solid tumors, often in combination

ENHERTU® (trastuzumab deruxtecan)* (*co‑developed/co‑commercialized)

Partners: Daiichi Sankyo (AstraZeneca holds significant share)
Indications: HER2‑positive and HER2‑low breast cancer, HER2‑mutant lung cancer, gastric cancer
Mechanism: Antibody‑drug conjugate (ADC) targeting HER2 linked to topoisomerase I inhibitor
Global Sales (2023, both partners): >$3B; AstraZeneca records a portion
Significance: Breakthrough ADC setting new standards in breast and lung cancer

LYNPARZA® (olaparib)* (*with Merck & Co.)

Indications: BRCA‑mutated ovarian, breast, pancreatic, and prostate cancers
Mechanism: PARP inhibitor
2023 Sales (global): ~$3–4B (shared with Merck; AZ reports its share)
Role: Maintenance therapy, combination with other agents

CALQUENCE® (acalabrutinib)

Indications: CLL/SLL, mantle cell lymphoma
Mechanism: BTK inhibitor (more selective vs ibrutinib)
2023 Sales: ~$2–3B

Additional Oncology Assets

Faslodex® (fulvestrant): ER+ breast cancer (mature, declining)
Daiichi Sankyo ADC deals: Beyond Enhertu (e.g., Dato‑DXd for lung and breast cancer)

2. CVRM (Cardiovascular, Renal & Metabolism)

CVRM is a major growth pillar, focusing on chronic cardiometabolic diseases.

FARXIGA® / FORXIGA® (dapagliflozin)

Indications: Type 2 diabetes, heart failure (HFrEF & HFpEF), chronic kidney disease (CKD)
Mechanism: SGLT2 inhibitor
2023 Sales: ~$5–6B
Strength: Shown to reduce CV death/hospitalization and slow CKD progression

BRILINTA® / BRILIQUE® (ticagrelor)

Indications: Acute coronary syndrome, post‑MI prevention
Mechanism: P2Y12 inhibitor antiplatelet
2023 Sales: ~$1.5–2B (maturing, competition from generics on horizon)

Crestor® (rosuvastatin) & legacy statins: Mostly off‑patent, contribute modest revenue.

3. Rare Disease (Alexion)

Acquired in 2021, Alexion brings a strong rare disease and complement biology franchise.

SOLIRIS® (eculizumab)

Indications: PNH (paroxysmal nocturnal hemoglobinuria), aHUS (atypical hemolytic uremic syndrome), gMG, NMOSD
Mechanism: C5 complement inhibitor
2023 Sales: ~$4B (declining as patients switch to Ultomiris)

ULTOMIRIS® (ravulizumab)

Indications: PNH, aHUS, gMG (generalized myasthenia gravis), expanding indications
Mechanism: Long‑acting C5 inhibitor (q8 weeks vs q2 weeks for Soliris)
2023 Sales: ~$2–3B (rapidly growing, replacing Soliris)

Other Alexion Assets

Strensiq® (asfotase alfa): Hypophosphatasia (HPP), ultra‑rare bone disease
Kanuma® (sebelipase alfa): LAL‑D (lysosomal acid lipase deficiency)

Strategy: Shift patients from Soliris to Ultomiris, expand into new complement-mediated diseases, develop next‑gen complement therapies.

4. Respiratory & Immunology

SYMBICORT® (budesonide/formoterol)

Indications: Asthma, COPD
Status: Major legacy product; facing generic erosion and competition

FASENRA® (benralizumab)

Indication: Severe eosinophilic asthma
Mechanism: IL‑5Rα monoclonal antibody, depletes eosinophils
2023 Sales: ~$1.5–2B (growing)
Expansions: Ongoing studies in COPD with eosinophilic phenotype

TEZSPIRE® (tezepelumab)* (*co‑developed with Amgen)

Indication: Severe asthma (broad, not limited to eosinophilic)
Mechanism: Anti‑TSLP (thymic stromal lymphopoietin)
Launch: Early stage; high potential as “pan‑type” severe asthma biologic

5. Other/Legacy & COVID‑19

COVID‑19 Vaccine (Vaxzevria)

Adenoviral vector vaccine developed with University of Oxford
Initially major product in 2021; largely phased out due to mRNA competition (Pfizer, Moderna) and demand shifts
Minimal contribution to 2023+ revenue

Other legacy brands: Losec/Prilosec, Nexium (PPIs), Seroquel (antipsychotic), etc. – largely generic.

Pipeline & R&D

AstraZeneca has one of the industry’s largest pipelines, with heavy focus on oncology, CVRM, immunology, and rare diseases.

Key Late‑Stage Programs (Illustrative)

Dato‑DXd (datopotamab deruxtecan): TROP2‑targeted ADC for lung and breast cancer (with Daiichi Sankyo)
Imfinzi combinations: With chemo, targeted agents, and other IO drugs across tumor types
Fasenra and Tezspire expansions: COPD, chronic rhinosinusitis with nasal polyps (CRSwNP), other airway diseases
Ultomiris expansions: Additional complement‑mediated disorders
CKD/CVRM assets: New indications and combinations for Farxiga

R&D Investment: ~$9–10B annually (~20% of revenue)

Geographic Revenue Mix

Region	% of Sales (approx.)	Notes
United States	~40%	Largest single market; high margins
Europe	~25%	UK, Germany, France, Italy, Nordics
Emerging Markets	~35%	China a very large growth driver; also Brazil, Russia, Middle East

Competitive Landscape

Oncology

Key competitors: Roche, Merck (Keytruda), Bristol Myers (Opdivo), Novartis, Pfizer, Daiichi Sankyo
AstraZeneca is top‑tier in lung cancer (Tagrisso, Imfinzi) and breast/others via ADC partnerships

CVRM

Competitors: Lilly (GLP‑1, tirzepatide), Novo Nordisk (GLP‑1), Jardiance (Boehringer/Lilly), Amgen (Repatha)
Farxiga is a key SGLT2 competitor with strong CV/renal data

Rare Disease

Competitors: Alexion’s prior standalone rivals (Sanofi, Roche, upcoming complement players)
Gene therapy entrants pose long‑term competition to chronic complement inhibition

Financial Performance

Revenue & Growth (approx.)

2019: ~$24B
2020: ~$26B
2021: ~$37B (includes first year Alexion, COVID vaccine)
2022: ~$44B (core business growth + Alexion; COVID tailwind)
2023: ~$45–47B (core growth offset COVID normalization)

Profitability (2023, continuing)

Core operating margin: ~30% (improving as scale increases)
Net margin: ~20–22% (adjusted)
ROIC: Trending higher as pipeline matures

Dividend & Capital Returns

Dividend yield: ~2–3%
Dividend history: Generally stable to growing, paid semi‑annually
Share buybacks: Opportunistic, used alongside M&A and R&D

Balance Sheet

Net debt: Elevated post‑Alexion but trending down
Credit rating: A‑/BBB+ range (investment grade)
Cash generation: Strong, supports deleveraging and growth initiatives

Investment Thesis

Bull Case 🐂

High‑growth Big Pharma: Faster revenue and EPS growth vs many peers
Diverse growth engines: Oncology, CVRM, rare diseases, respiratory
Strong pipeline: Particularly in ADCs, lung cancer, complement biology
Emerging markets strength: Especially China, where AZ has deep roots
Attractive mix: Growth + dividend (~2–3%)

Bear Case 🐻

Patent risk: Future LOEs (Tagrisso, Farxiga, etc.) in the 2030s
Pipeline execution: Need high success rate to justify premium valuation
Competition: Intense in all key areas (oncology, CVRM, rare diseases)
Regulatory/pricing pressure: Medicare negotiations, EU price controls, China VBP
Integration risk: Alexion rare disease business must continue to perform

Valuation Snapshot (Indicative)

Forward P/E: ~18–20x
P/S: ~5–6x
EV/EBITDA: ~13–15x
Dividend yield: ~2–3%

Typically trades at a premium to slower‑growing European pharma peers, but below ultra‑high‑growth names like Eli Lilly and Novo Nordisk.

How to Invest in AstraZeneca

Direct Stock Purchase

US ADR: NASDAQ: AZN (1 ADR = 1 ordinary share)
UK listing: LSE: AZN (trades in GBP)
Highly liquid on both exchanges

ETF Exposure

Health Care Select Sector SPDR (XLV) – modest AZN weighting
Vanguard FTSE Europe ETF (VGK) – AZN as a top holding
iShares MSCI United Kingdom ETF (EWU) – significant AZN exposure

Tax Considerations (US Investors)

Dividends

UK‑domiciled company; no UK withholding tax on dividends for most US investors
Dividends generally treated as qualified (lower tax rate) if holding period met

Capital Gains

Standard US capital gains rules for the ADR

ESG Considerations

Environmental

Net‑zero emissions target by 2045
“Ambition Zero Carbon” program for operations and supply chain

Social

Access‑to‑medicine programs, tiered pricing in low‑income countries
Active in global health partnerships (TB, malaria, NCDs)

Governance

Independent board, separation of Chair and CEO roles
Good track record under Pascal Soriot of pipeline execution and capital allocation

ESG Ratings: Generally strong (AA/AAA range from major providers).

Related Terms

EGFR TKI – Tyrosine kinase inhibitor targeting EGFR mutations (Tagrisso)
PD‑L1 inhibitor – Immune checkpoint inhibitor (Imfinzi)
ADC (Antibody‑Drug Conjugate) – Antibody linked to cytotoxic drug (Enhertu, Dato‑DXd)
SGLT2 inhibitor – Diabetes/heart/renal drug class (Farxiga)
C5 inhibitor – Complement pathway blocker (Soliris, Ultomiris)
LOE (Loss of Exclusivity) – Patent expiry and generic entry

Disclaimer: This information is for educational purposes only and does not constitute financial or medical advice. AstraZeneca stock carries risks including clinical trial failures, patent expiries, regulatory and pricing pressure, FX volatility, and competitive threats. DYOR before making investment decisions. Past performance is not indicative of future results.

Official Website: www.astrazeneca.com

Investor Relations: www.astrazeneca.com/investor-relations.html

NASDAQ Listing: www.nasdaq.com (Code: AZN)

LSE Listing: London Stock Exchange (Code: AZN)

SEC Filings (ADR): www.sec.gov (Search: AstraZeneca PLC)

Related Topics: AstraZeneca, AZN, Oncology Stocks, CVRM, Rare Diseases, Alexion Acquisition, Tagrisso, Imfinzi, Farxiga, Soliris, Ultomiris, Enhertu, ADCs, Big Pharma, UK Stocks, Dividend Stocks, Growth Pharma

AstraZeneca plc (NASDAQ: AZN)